Year Founded
2022
Ownership
Private
Therapeutic Areas
Oncology
Stage
Preclinical
Modalities
Small molecule

Sentonix Pharma General Information

Developing orally available immunotherapy drugs that aim to enhance immune response against cancer with minimal side effects. Building on research from The Kids Research Institute Australia and University of Western Australia.

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office
Boston, Massachusetts
United States

Drug Pipeline

LB1410
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Sentonix Pharma's pipeline data

Book a demo

Key Partnerships

The Kids Research Institute Australia, University of Western Australia

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Sentonix Pharma Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Sentonix Pharma's complete valuation and funding history, request access »

Sentonix Pharma Investors

CUREator grant via Brandon BioCatalyst funded by Australia's Medical Research Future Fund.
Investor Type: Venture Capital
Holding: Minority